These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 32224561)

  • 1. Poor response to daratumumab and carfilzomib in newly diagnosed anaplastic multiple myeloma.
    Saburi M; Ogata M; Soga Y; Kondo Y; Kurimoto R; Itani K; Kohno K; Uchida H; Nakayama T
    J Clin Exp Hematop; 2020; 60(1):17-20. PubMed ID: 32224561
    [No Abstract]   [Full Text] [Related]  

  • 2. Outcome of treatment with carfilzomib before and after treatment with daratumumab in relapsed or refractory multiple myeloma patients.
    Højholt KL; Gregersen H; Szabo AG; Klausen TW; Levring MB; Preiss B; Helleberg C; Breinholt MF; Hermansen E; Rahbek Gjerdrum LM; Bønløkke ST; Nielsen K; Kjeldsen E; Iversen KF; Teodorescu EM; Kurt E; Strandholdt C; Andersen MK; Vangsted AJ
    Hematol Oncol; 2021 Oct; 39(4):521-528. PubMed ID: 34342035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modern treatments and future directions for newly diagnosed multiple myeloma patients.
    Lu SX
    Best Pract Res Clin Haematol; 2020 Mar; 33(1):101151. PubMed ID: 32139016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Limited efficacy of daratumumab in multiple myeloma with extramedullary disease.
    Jelinek T; Sevcikova T; Zihala D; Popkova T; Kapustova V; Broskevicova L; Capkova L; Rihova L; Bezdekova R; Sevcikova S; Zidlik V; Havel M; Plonkova H; Jungova A; Minarik J; Stork M; Pour L; Pavlicek P; Spicka I; Maisnar V; Radocha J; Simicek M; Hajek R
    Leukemia; 2022 Jan; 36(1):288-291. PubMed ID: 34247197
    [No Abstract]   [Full Text] [Related]  

  • 5. High-risk smoldering myeloma versus early detection of multiple myeloma: Current models, goals of therapy, and clinical implications.
    Kunacheewa C; Manasanch EE
    Best Pract Res Clin Haematol; 2020 Mar; 33(1):101152. PubMed ID: 32139017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy.
    Quach H; Nooka A; Samoylova O; Venner CP; Kim K; Facon T; Spencer A; Usmani SZ; Grosicki S; Suzuki K; Delimpasi S; Weisel K; Obreja M; Zahlten-Kumeli A; Mateos MV
    Br J Haematol; 2021 Aug; 194(4):784-788. PubMed ID: 34046887
    [No Abstract]   [Full Text] [Related]  

  • 7. New developments in the management and treatment of newly diagnosed and relapsed/refractory multiple myeloma patients.
    van de Donk NW; Lokhorst HM
    Expert Opin Pharmacother; 2013 Aug; 14(12):1569-73. PubMed ID: 23721099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. American Society of Hematology Annual Meeting 2014: highlights in multiple myeloma.
    Glavey SV; Ghobrial IM
    Expert Rev Hematol; 2015 Jun; 8(3):273-5. PubMed ID: 25804827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carfilzomib maintenance in newly diagnosed non-transplant eligible multiple myeloma.
    Bobin A; Kyheng M; Guidez S; Gruchet-Merouze C; Richez V; Duhamel A; Karlin L; Kolb B; Tiab M; Araujo C; Meuleman N; Malfuson JV; Bourquard P; Lenain P; Perrot A; Roussel M; Jaccard A; Petillon MO; Belhadj-Merzoug K; Chretien ML; Fontan J; Rodon P; Schmitt A; Offner F; Voillat L; Cereja S; Kuhnowski F; Rigaudeau S; Decaux O; Humbrecht-Kraut C; Frayfer J; Fitoussi O; Roos-Weil D; Eisenmann JC; Dorvaux V; Voog EG; Moreau P; Avet-Loiseau H; Hulin C; Facon T; ; Leleu X
    Leukemia; 2022 Mar; 36(3):881-884. PubMed ID: 34650225
    [No Abstract]   [Full Text] [Related]  

  • 10. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study.
    Dimopoulos M; Quach H; Mateos MV; Landgren O; Leleu X; Siegel D; Weisel K; Yang H; Klippel Z; Zahlten-Kumeli A; Usmani SZ
    Lancet; 2020 Jul; 396(10245):186-197. PubMed ID: 32682484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Kinetic characteristics of tumor growth in multiple myeloma].
    Golenkov AK; Kasatkina VV; Kozinets GI; Zlatkina AR
    Gematol Transfuziol; 1988 Dec; 33(12):34-6. PubMed ID: 3234732
    [No Abstract]   [Full Text] [Related]  

  • 12. Multiple myeloma: Current advances and future directions.
    Ola Landgren C
    Best Pract Res Clin Haematol; 2020 Mar; 33(1):101155. PubMed ID: 32139007
    [No Abstract]   [Full Text] [Related]  

  • 13. High-Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action.
    Adams HC; Stevenaert F; Krejcik J; Van der Borght K; Smets T; Bald J; Abraham Y; Ceulemans H; Chiu C; Vanhoof G; Usmani SZ; Plesner T; Lonial S; Nijhof I; Lokhorst HM; Mutis T; van de Donk NWCJ; Sasser AK; Casneuf T
    Cytometry A; 2019 Mar; 95(3):279-289. PubMed ID: 30536810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safe Use of Carfilzomib in a Patient with Multiple Myeloma and Intermittent Type 1 Brugada ECG Pattern: A Case Report.
    Ghisoni E; Marandino L; Lombardi P; Bonzano A; Becco P; Aglietta M; Fizzotti M; Gay F; Rota Scalabrini D
    Acta Haematol; 2020; 143(5):481-485. PubMed ID: 31553985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Daratumumab for multiple myeloma].
    Croizier C; Bailly S
    Bull Cancer; 2018 Nov; 105(11):985-991. PubMed ID: 30430991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An overview of the role of carfilzomib in the treatment of multiple myeloma.
    Ziogas DC; Terpos E; Kastritis E; Dimopoulos MA
    Expert Opin Pharmacother; 2017 Dec; 18(17):1883-1897. PubMed ID: 29134824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrating novel agents into multiple myeloma treatment - current status in Switzerland and treatment recommendations.
    Taverna C; Bargetzi M; Betticher D; Gmür J; Gregor M; Heim D; Hess U; Ketterer N; Lerch E; Matthes T; Mey U; Pabst T; Renner C
    Swiss Med Wkly; 2010; 140():w13054. PubMed ID: 20458652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of daratumumab in dialysis-dependent renal failure secondary to multiple myeloma.
    Rocchi S; Tacchetti P; Pantani L; Mancuso K; Zannetti B; Cavo M; Zamagni E
    Haematologica; 2018 Jun; 103(6):e277-e278. PubMed ID: 29622654
    [No Abstract]   [Full Text] [Related]  

  • 19. Carfilzomib for the treatment of multiple myeloma.
    Lue J; Goel S; Mazumder A
    Drugs Today (Barc); 2013 Mar; 49(3):171-9. PubMed ID: 23527321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Considerations for pre-transfusion immunohaematology testing in patients receiving the anti-CD38 monoclonal antibody daratumumab for the treatment of multiple myeloma.
    Quach H; Benson S; Haysom H; Wilkes AM; Zacher N; Cole-Sinclair M; Miles Prince H; Mollee P; Spencer A; Joy Ho P; Harrison SJ; Lee C; Augustson B; Daly J
    Intern Med J; 2018 Feb; 48(2):210-220. PubMed ID: 29415351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.